These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 35206286)

  • 1. Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients-The Debate Is Still Open.
    Kruszewska J; Laudy-Wiaderny H; Kunicki M
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China.
    Wang L; Lv S; Li F; Yu X; Bai E; Yang X
    Front Endocrinol (Lausanne); 2020; 11():171. PubMed ID: 32296394
    [No Abstract]   [Full Text] [Related]  

  • 3. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
    Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
    Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome.
    Alves MT; de Souza IDP; Ferreira CN; Cândido AL; Bizzi MF; Oliveira FR; Reis FM; Gomes KB
    Gynecol Endocrinol; 2020 Sep; 36(9):760-763. PubMed ID: 32157924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of decreased myonectin levels with metabolic and hormonal disturbance in polycystic ovary syndrome.
    Demir İ; Guler A
    Gynecol Endocrinol; 2020 Nov; 36(11):947-950. PubMed ID: 32314610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preptin in women with polycystic ovary syndrome.
    Mierzwicka A; Kuliczkowska-Plaksej J; Kolačkov K; Bolanowski M
    Gynecol Endocrinol; 2018 Jun; 34(6):470-475. PubMed ID: 29374985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome.
    Pawelczak M; Rosenthal J; Milla S; Liu YH; Shah B
    J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):356-9. PubMed ID: 25256873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating neuregulin-1 levels in polycystic ovary syndrome.
    Arpacı H
    J Obstet Gynaecol; 2019 May; 39(4):504-509. PubMed ID: 30634887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome.
    Kort DH; Kostolias A; Sullivan C; Lobo RA
    Gynecol Endocrinol; 2015 Feb; 31(2):152-5. PubMed ID: 25295622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of interlukin-6 on central obesity measures in women with polycystic ovarian syndrome.
    Alissa EM; Algarni SA; Khaffji AJ; Al Mansouri NM
    J Obstet Gynaecol; 2020 Nov; 40(8):1133-1137. PubMed ID: 32157932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome.
    Lewy VD; Danadian K; Witchel SF; Arslanian S
    J Pediatr; 2001 Jan; 138(1):38-44. PubMed ID: 11148510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine and metabolic characteristics in polycystic ovary syndrome.
    Glintborg D
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance, polycystic ovary syndrome and metformin.
    Pugeat M; Ducluzeau PH
    Drugs; 1999; 58 Suppl 1():41-6; discussion 75-82. PubMed ID: 10576524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome.
    Rasool SUA; Ashraf S; Nabi M; Rashid F; Fazili KM; Amin S
    Diabetes Metab Syndr; 2019; 13(3):2098-2105. PubMed ID: 31235143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China.
    Huang J; Ni R; Chen X; Huang L; Mo Y; Yang D
    Reprod Biol Endocrinol; 2010 Nov; 8():142. PubMed ID: 21083920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
    Naderpoor N; Shorakae S; de Courten B; Misso ML; Moran LJ; Teede HJ
    Hum Reprod Update; 2015; 21(5):560-74. PubMed ID: 26060208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.